Frazier Life Sciences Acquisition Corp. II Prices $78 Million IPO to Target Biotech Sector

Key numbers

Deal value	$78M
Share of market cap	76.9%

Key highlights

• Initial public offering of 7,500,000 Class A ordinary shares priced at $10.00 each
• Sponsor purchased 300,000 private placement shares for $3 million in additional proceeds
• Forward purchase agreement secures a minimum of $25 million for a future business combination
• Shares commenced trading on the Nasdaq Capital Market under the ticker symbol FLSC
• Company has a 24-month deadline ending October 2028 to consummate an acquisition

Structure of the Capital Raise

Frazier Life Sciences Acquisition Corp. II finalized its initial public offering on October 15, 2026, issuing 7.5 million Class A ordinary shares at a par value of $0.0001 per share. Jefferies LLC acted as the sole book-running manager for the transaction. In addition to the 75 million dollars raised through the public offering, the company's sponsor, Frazier Life Sciences Holdings II, LLC, purchased 300,000 private placement shares at the same 10 dollar price point. This brings the immediate capital injection to 78 million dollars. Furthermore, a forward purchase agreement with Frazier Life Sciences Public Fund, L.P. ensures at least 25 million dollars in additional funding upon the closing of a future merger.

Strategic Focus and Management

The company was formed specifically to execute a merger, share exchange, or similar business combination with a focus on the biotechnology sector. The leadership team includes Chief Executive Officer Albert Cha, M.D., Ph.D., and Chairman Ben Palleiko, who intend to identify therapeutic developers with high clinical potential. This acquisition strategy aims to capitalize on the team's deep industry experience to bring new treatments to market. While the search is global, the firm prioritizes companies that can benefit from the institutional backing of the Frazier Life Sciences affiliate network and its established presence in Palo Alto, California.

Financial Framework and Timeline

• Total net proceeds from the IPO and private placement are held in a trust account managed by Continental Stock Transfer and Trust Company
• The company is an emerging growth company as defined by the Securities Act of 1933, allowing for reduced reporting requirements
• A two-year window ending October 15, 2028, has been established for the completion of an initial business combination
• Failure to close a transaction within the 24-month period will trigger a liquidation and winding-up process for the trust funds
• Class B ordinary founder shares held by the sponsor represent the initial equity base prior to public participation

Industry Context

The launch of FLSC comes amid a selective environment for healthcare-focused special purpose acquisition companies. By targeting the biotechnology space, the company enters a sector characterized by high capital intensity and significant regulatory milestones. Funding trends in the industry have recently favored SPACs led by experienced clinical and financial operators who can provide more than just capital, such as strategic guidance for navigating FDA approval pathways. The inclusion of a forward purchase agreement suggests a commitment to ensuring sufficient liquidity for a target's mid-to-late stage clinical development upon the eventual merger.

Frazier Life Sciences Acquisition Corp. II · financial snapshot

Share price	$10.49
Market cap	$101M
Sector	Financial ServicesShell Companies

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.